These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28057790)

  • 1. Novel Risk Markers and Risk Assessments for Cardiovascular Disease.
    Thomas MR; Lip GY
    Circ Res; 2017 Jan; 120(1):133-149. PubMed ID: 28057790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury.
    Viereck J; Thum T
    Circ Res; 2017 Jan; 120(2):381-399. PubMed ID: 28104771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of the new cardiovascular risk markers in diabetes mellitus.
    Iglesias P; Pedro-Botet J; Arrieta F; Aguilar M; Escobar On Behalf Of The Working Group On Diabetes And Cardiovascular Disease Of The Spanish Society Of Diabetes F
    Curr Diabetes Rev; 2015; 11(4):273-80. PubMed ID: 25808417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating biomarkers.
    Badimon L; Romero JC; Cubedo J; Borrell-Pagès M
    Thromb Res; 2012 Oct; 130 Suppl 1():S12-5. PubMed ID: 23026650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar.
    Welsh P; Packard CJ; Sattar N
    Curr Opin Lipidol; 2008 Dec; 19(6):563-71. PubMed ID: 18957878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?
    Fichtlscherer S; Zeiher AM; Dimmeler S
    Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2383-90. PubMed ID: 22011751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases.
    Sayed AS; Xia K; Salma U; Yang T; Peng J
    Heart Lung Circ; 2014 Jun; 23(6):503-10. PubMed ID: 24726001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease.
    Bank IE; Timmers L; Gijsberts CM; Zhang YN; Mosterd A; Wang JW; Chan MY; De Hoog V; Lim SK; Sze SK; Lam CS; De Kleijn DP
    Expert Rev Mol Diagn; 2015; 15(12):1577-88. PubMed ID: 26535492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools.
    Marcovina SM; Crea F; Davignon J; Kaski JC; Koenig W; Landmesser U; Pieri PL; Schulz-Menger J; Shaw LJ; Sobesky J
    J Intern Med; 2007 Mar; 261(3):214-34. PubMed ID: 17305644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying new Risk Markers and Potential Targets: The Value of the Proteome.
    Kontush A
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):13-8. PubMed ID: 26931819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application.
    Kim SH; Weiß C; Hoffmann U; Borggrefe M; Akin I; Behnes M
    Curr Pharm Biotechnol; 2017; 18(6):445-455. PubMed ID: 28571562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of cardiac biomarkers in cardiovascular disease risk assessment.
    Collinson P
    Curr Opin Cardiol; 2014 Jul; 29(4):366-71. PubMed ID: 24848409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do novel biomarkers add to existing scores of total cardiovascular risk?
    De Backer G; Graham I; Cooney MT
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):14-7. PubMed ID: 22801065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease.
    Gupta SK; Bang C; Thum T
    Circ Cardiovasc Genet; 2010 Oct; 3(5):484-8. PubMed ID: 20959591
    [No Abstract]   [Full Text] [Related]  

  • 15. Critical appraisal of inflammatory markers in cardiovascular risk stratification.
    Krintus M; Kozinski M; Kubica J; Sypniewska G
    Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond cardiac troponin: recent advances in the development of alternative biomarkers for cardiovascular disease.
    Rubini Gimenez M; Twerenbold R; Mueller C
    Expert Rev Mol Diagn; 2015 Apr; 15(4):547-56. PubMed ID: 25676700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of Metabolic Syndrome: Biochemical Background and Clinical Significance.
    Robberecht H; Hermans N
    Metab Syndr Relat Disord; 2016 Mar; 14(2):47-93. PubMed ID: 26808223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis.
    Koenig W
    Ann Med; 2009; 41(5):332-43. PubMed ID: 19291518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in platelet toll-like receptors and their association with cardiovascular risk factors.
    Koupenova M; Mick E; Mikhalev E; Benjamin EJ; Tanriverdi K; Freedman JE
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):1030-7. PubMed ID: 25657311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidate circulating biomarkers for the cardiovascular disease continuum.
    Dotsenko O; Chackathayil J; Patel JV; Gill PS; Lip GY
    Curr Pharm Des; 2008; 14(24):2445-61. PubMed ID: 18781994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.